Drug Trial Radar · NCT07622706
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 3, 2026
Primary completion
Dec 30, 2029
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Peking University Cancer Hospital & InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma. The goal of this study was to evaluate the efficacy of firmonertinib neoadjuvant in patients with resectable stage II-IIIB EGFR-mutated non-small cell lung cancer (NSCLC) by major pathologic response (MPR).
Conditions
- NSCLC
- EGFR Positive Non-small Cell Lung Cancer
- Neoadjuvant Therapy
Interventions
Firmonertinib 80mg qd oral for 8 weeks.Drug
Participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral for 8 weeks. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.
Firmonertinib 160mg qd oral for 8 weeks.Drug
Participations will receive the drug treatments preoperatively: Firmonertinib 160mg qd oral for 8 weeks. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.
Firmonertinib 80mg qd oral for 16 weeks.Drug
Participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral for 16 weeks. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.
Radical resectionProcedure
Radical resection of the tumor will be performed within 3-4 weeks after the end of treatment.
firmonertinib adjuvant therapyDrug
After surgery, participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral as adjuvant therapy for 3 years. The investigator may decide whether to add chemotherapy or to change other adjuvant treatment modalities.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Pathological Response (MPR) RateTime frame: At the time of surgery (approximately Week 12 from treatment initiation for Cohort 1 and Cohort 2, and Week 20 for Cohort 3), Assessed up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital & Institute
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.